Table 1.
Patients baseline demographics and disease characteristics
| Characteristic | Topotecan 1.5 mg/m2 IV daily for 5 days Q3W | Topotecan 0.5 mg/m2 IV daily for 5 days Q3W | All patients (N = 14) | |
|---|---|---|---|---|
| Selinexor 60 mg PO BIW (n = 2) | Selinexor 60 mg PO QW (n = 6) | Selinexor 80 mg PO QW (n = 6) | ||
| Age at consent (years) | ||||
| Median Range | 49.8 (44.0-55.5) | 61.2 (21.6–68.4) | 63.2 (56.1–68.0) | 60.5 (21.6–68.4) |
| Gender, n (%) | ||||
| Male | 0 | 1 (17) | 2 (33) | 3 (21) |
| Female | 2 (100) | 5 (83) | 4 (67) | 11 (79) |
| Race, n (%) | ||||
| White | 1 (50) | 3 (50) | 6 (100) | 10 (71) |
| Hispanic | 1 (50) | 3 (50) | 0 | 4 (29) |
| Black | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| ECOG performance status, n (%) | ||||
| 0 | 1 (50) | 0 | 0 | 1 (7) |
| 1 | 1 (50) | 6 (100) | 6 (100) | 13 (93) |
| Primary tumor, n (%) | ||||
| Ovarian | 2 (100) | 2 (33) | 1 (17) | 5 (36) |
| Breast | 0 | 0 | 0 | 0 |
| Colorectal Cancer | 0 | 1 (17) | 0 | 1 (7) |
| Endometrial/fallopian | 0 | 1 (17) | 2 (33) | 3 (21) |
| Lung | 0 | 0 | 0 | 0 |
| Neuroendocrine | 0 | 0 | 1 (17) | 1 (7) |
| Pancreas | 0 | 0 | 0 | 0 |
| Esophageal | 0 | 0 | 0 | |
| Head & Neck/salivary gland | 0 | 0 | 0 | 0 |
| Liver/cholangiocarcinoma | 0 | 0 | 0 | 0 |
| Sarcoma | 0 | 0 | 1 (17) | 1 (7) |
| Prostate | 0 | 0 | 0 | 0 |
| Others | 0 | 2 (33)* | 1 (17)** | 3 (21) |
| Prior lines of systemic therapies, n (%) | ||||
| 0–1 | 0 | 0 | 2 (33) | 2 (14) |
| 2–3 | 0 | 2 (33) | 2 (33) | 4 (29) |
| 4–5 | 1 (50) | 3 (50) | 1 (17) | 5 (36) |
| > 5 | 1 (50) | 1 (17) | 1 (17) | 3 (21) |
Abbreviations: BIW, twice weekly dosing schedule; ECOG, Eastern Cooperative Oncology Group; IV, intravenous; PO, oral; Q3W, 3 weekly dosing schedule; QW, weekly dosing schedule
* includes desmoid fibromatosis, and adenocarcinoma of unknown primary
** includes malignant mesothelioma (epitheliod type)